Rich is championing patient-centered healthcare solutions to: Create Pricing transparency to force prices down through competition
Create pricing transparency to force prices down through competition.
Occurrences
Evidence
The press release says McCormick co-led the CLEAR LABELS Act, which would require prescription drug labels to clearly list the original manufacturers of both the drugs and their APIs, 'giving Americans the transparency they deserve' and 'bringing transparency to consumers, pharmacists, and providers' about where medications come from.
McCormick's healthcare page states that drug prices are unreasonably high and that 'Promoting transparency and real competition is crucial to help lower costs and improve access to medications.'
The member page shows McCormick's introduced bill H.R.5438 (Incentivize Savings Act) had only committee action as of February 4, 2026, and the page overall lists his bills and actions without indicating enactment of a pricing-transparency law.
Assessments
McCormick appears to have taken concrete action consistent with the promise by co-leading transparency legislation such as the CLEAR LABELS Act and by advancing other cost/competition-related bills. However, the available evidence does not show that he enacted a pricing-transparency policy that actually forced prices down through competition, which is the core promised outcome. Because he materially pursued the goal but there is no evidence of full delivery or enactment, partial credit is most appropriate.